Physician profile
Khalid Sherani
NPI 1760873293
$2,111.63
in general payments reported to CMS, 2019-2025
16 companies · $16.57 in 2025
The $16.57 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $257 · 2021: $1,169 · 2022: $37.05 · 2023: $216 · 2024: $14.50 · 2025: $16.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill-Rom Services, INC | $875.00 | 2021 | |
| Abiomed | $386.27 | 2021-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $168.36 | 2020 | |
| Genentech USA, INC. | $138.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $132.04 | 2021 | |
| Paratek Pharmaceuticals, INC. | $119.02 | 2019-2020 | |
| Glaxosmithkline, LLC. | $102.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.51 | 2020 | |
| Ekos Corporation | $27.63 | 2019 | |
| Smith+Nephew, INC. | $23.49 | 2021 | |
| Grifols USA, LLC | $22.74 | 2020 | |
| Melinta Therapeutics, LLC | $21.71 | 2022 | |
| Mylan Specialty L.P. | $16.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Edwards Lifesciences Corporation | $14.50 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Sherani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.